



03-01-07

PTO/SB/21 (09-04)

1638

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number	10/088,830		
	Filing Date	August 26, 2002	
	First Named Inventor	Crisanto Gutierrez-Armenta	
	Art Unit	1638	
	Examiner Name	Cynthia Collins	
Total Number of Pages in This Submission		Attorney Docket Number	141183US1 (BTG0004-100)

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached/Authorized <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Forms PTO SB/08a and SB/08b (15 pp.); (198) References Cited; (149) reference copies provided; Return Card.
Remarks EXPRESS MAIL LABEL NO. : EV 770972231 US DATE OF DEPOSIT : February 27, 2007		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm	Cozen O'Connor		
Signature			
Printed Name	Paul K. Legaard, Ph.D.		
Date	February 27, 2007	Reg. No.	38,534


CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Signature	
Typed or printed name	Date

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



BEG0004-100 (141183US1)

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: **Crisanto Gutierrez-Armenta et al.**

Serial No.: **10/088,830**

Group Art Unit: **1638**

Filing Date: **August 26, 2002**

Examiner: **Cynthia Collins**

Title: **WHEAT DP PROTEINS AND USES THEREOF**

EXPRESS MAIL LABEL NO. : EV 770972231 US
DATE OF DEPOSIT : February 27, 2007

MAIL STOP AMENDMENT

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

03/02/2007 CNEGA1 00000027 501275 10000030

01 FC:1006 100.00 DA

Dear Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §§ 1.56 and in accordance with 37 C.F.R. §§ 1.97 and 1.98, information relating to the above-identified application is hereby disclosed, the Examiner in charge of the above-identified application is requested to consider and make of record the references listed on the PTO Forms SB/08A and SB/08B, formerly known as PTO Form 1449 submitted herewith.

Inclusion of the information submitted herewith is not to be construed as an admission that the information is material as that term is defined in 37 C.F.R. § 1.56(b).

In accordance with 37 C.F.R. § 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.

This Information Disclosure Statement is being filed:

- ☐ within three months of the filing date of the patent application.
- ☐ within three months of the date of entry into the national stage as set forth in 37 C.F.R. § 1.491 of the international application.
- ☐ **before** the mailing date of a first Office Action on the merits.
- ☒ **after** the mailing date of a first Office Action on the merits, but before the mailing date of a Final Office Action under 37 C.F.R. § 1.116 or a Notice of Allowance under 37 C.F.R. § 1.311, and accordingly is accompanied by:

- ☐ the Statement under 37 C.F.R. § 1.97(e) (see "Statement" below);
- or**
- ☐ the Fee of \$180.00 set forth in 37 C.F.R. § 1.17(p); or
- ☐ No fee is owed by the applicant(s).
- ☐ In accordance with 37 C.F.R. § 1.129(a), this Information Disclosure Statement is being filed in connection with ☐ the first or ☐ second After Final Submission, and accordingly is accompanied by the Statement under 37 C.F.R. § 1.97(e) (see "Statement" below) and the fee of \$180.00 as set forth in 37 C.F.R. § 1.17(p), is attached.
- ☐ **after** the mailing date of a Final Office Action under 37 C.F.R. § 1.116 or a Notice of Allowance under 37 C.F.R. § 1.311, but before the payment of the Issue Fee, and accordingly is accompanied by the Statement under 37 C.F.R. § 1.97(e), (see "Statement," and "Fees" below).
- ☒ Copies of the references (except the U.S. Patent documents) listed on the attached PTO Forms SB/08A and SB/08B, formerly known as PTO Form 1449 are enclosed.

EXCEPT THAT:

- ☒ In view of the voluminous nature of reference GH, and the likelihood that the reference is available to the Examiner, a copy is not enclosed herewith.
- ☐ In accordance with 37 C.F.R. § 1.98(d), copies of all references listed on the attached PTO Form SB/08A, formerly known as PTO Form 1449 are not enclosed herewith because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application for which a claim for priority under 35 U.S.C. § 120 has been made in the instant application.
- ☐ If the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.

Statement under 37 C.F.R. § 1.97(e)

- ☐ The undersigned attorney hereby states that each item information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application not more than three months prior to the filing of the Information Disclosure Statement.

Fees

- ☐ No Fee is owed by the applicant(s).
- ☒ The Information Disclosure Statement Fee of \$180.00 under 37 C.F.R. § 1.17(p) is enclosed herewith.

Method of Payment of Fees

- ☐ Attached is a check in the amount of \$_____. This form is submitted in duplicate.
- ☒ Charge Deposit Account No. 50-1275 in the amount of \$180.00. This form is submitted in duplicate.
- ☒ Please charge any deficiency or credit any overpayment to Deposit Account 50-1275.
- ☐ No fee or Statement is required under 37 C.F.R. § 1.97(b).

Respectfully submitted,



Paul K. Legaard, Ph.D.
Registration No. 38,534

Dated: February 27, 2007

COZEN O'CONNOR, P.C.
1900 Market Street, 5th Floor
Philadelphia, PA 19103-3508
(215) 665-2000 – Telephone
(215) 701-2013 - Facsimile



Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 15

Complete if Known

Application Number	10/088,830
Filing Date	August 26, 2002
First Named Inventor	Crisanto Gutierrez-Armenta
Art Unit	1638
Examiner Name	Cynthia Collins
Attorney Docket Number	141183US01 (BTG0004-100)

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number	Publication/Issue Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
	AA	US-5,859,328	01-12-1999	Nasrallah et al	
	AB	US-5,792,925	08-11-1998	de Framond	
	AC	US-5,689,044	11-18-1997	Ryals et al	
	AD	US-5,670,349	09-03-1997	Cramer et al	
	AE	US-5,646,333	07-08-1996	Dobres et al	
	AF	US-5,633,363	05-27-1997	Colbert et al	
	AG	US-5,629,183	05-13-1997	Saunders et al	
	AH	US-5,618,988	04-10-1997	Hauptmann et al	
	AI	US-5,589,610	12-31-1996	De Beuckeleer et al	
	AJ	US-5,589,583	12-31-1996	Klee et al	
	AK	US-5,565,346	10-15-1996	Facciotti	
	AL	US-5,554,798	09-10-1996	Lundquist et al.	
	AM	US-5,538,877	07-23-1996	Lundquist et al.	
	AN	US-5,510,318	04-23-1996	Patel et al.	
	AO	US-5,508,468	04-16-1996	Lundquist et al.	
	AP-	US-5,495,007	02-27-1996	Thompson et al	
	AQ	US-5,489,520	02-06-1996	Adams et al.	
	AR	US-5,484,956	01-16-1996	Lundquist et al.	
	AS	US-5,478,744	12-26-1995	Sanford et al.	
	AT	US-5,464,763	11-07-1995	Schilperoort et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document	Publication Date/Filing Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
	AU	WO98/56811	12/17/98	Consejo Superior De Investigaciones Cientificas		
	AV	WO99/58681	11/18/99	Consejo Superior De Investigaciones Certificas		
	AW	WO97/47745	12/18/97	Cons. Sup. De Investigaciones Cert		
	AX	WO97/20058	06/05/97	Bay Zoltan Alkalmazott Kutatasi Alapitva		
	AY	EP 905 236	03/31/99	Med. Res. Council		
	AZ	WO99/53075	10/21/99	Du Pont		
	BA	WO00/47614	08/17/00	Pioneer Hi Bred Int.		
	BB	EP 0905518	03-31-1999	Konig		
	BC	WO 01/25793	04-12-2001	ISIS Innovation		

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2 of 15

Complete if Known

Application Number	10/088,830
Filing Date	August 26, 2002
First Named Inventor	Crisanto Gutierrez-Armenta
Art Unit	1638
Examiner Name	Cynthia Collins
Attorney Docket Number	141183US01 (BTG0004-100)

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number	Publication/Issue Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
	BD	US-5,459,252	10-17-1995	Conkling et al	
	BE	US-5,428,146	06-27-1995	Logemann et al	
	BF	US-5,405,765	04-11-1995	Vasil et al.	
	BG	US-5,371,014	12-06-1994	Matsuyama et al.	
	BH	US-5,356,799	10-18-1994	Fabijanski et al	
	BI	US-5,250,515	10-05-1993	Fuchs et al	
	BJ	US-5,204,253	04-20-1993	Sanford et al.	
	BK	US-5,202,257	04-13-1993	Heinemann et al	
	BL	US-5,187,267	02-16-1993	Comai et al	
	BM	US-5,187,073	02-16-1993	Goldman et al.	
	BN	US-5,179,022	01-12-1993	Sanford et al.	
	BO	US-5,177,010	01-05-1993	Goldman et al.	
	BP	US-5,110,732	05-05-1992	Benfey et al	
	BQ	US-5,107,065	04-21-1992	Shewmaker et al	
	BR	US-5,100,792	03-31-1992	Sanford et al.	
	BS	US-5,097,025	03-17-1992	Benfey et al	
	BT	US-5,086,169	02-04-1992	Mascarenhas	
	BU	US-5,036,006	07-30-1991	Sanford et al.	
	BV	US-4,945,050	07-31-1990	Sanford et al.	
	BW	US-4,943,674	07-24-1990	Houck et al	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date/Filing Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
	BX	EP 0255378	02-03-1988	Calgene		
	BY	WO 92/17580	10-15-1992	Rhone-Poulenc		
	BZ	WO 98/45460	10-15-1998	Rhone-Poulenc		
	CA	WO 98/45461	10-15-1998	Rhone-Poulenc		
	CB	EP 267159	05-11-1988	Ciba-Geigy		
	CC	EP 604662	07-06-1994	Japan Tobacco		
	CD	EP 672752	09-20-1995	Japan Tobacco		
	CE	EP 442174	08-21-1991	Pioneer Hi-Bred		
	CF	EP 486233	05-20-1992	Pioneer Hi-Bred		

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/088,830
				Filing Date	August 26, 2002
				First Named Inventor	Crisanto Gutierrez-Armenta
				Art Unit	1638
				Examiner Name	Cynthia Collins
				Attorney Docket Number	141183US01 (BTG0004-100)
Sheet	3	of	15		

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date/Filing Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ^a
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
	CO	EP486234	05-20-1992	Pioneer Hi-Bred		
	CP	EP 539563	10-17-2001	Monsanto		
	CQ	WO 94/13863	06-23-1994	Amorphous		
	CR	WO 91/02071	02-21-1991	DeKalb Plant Genetics		
	CS	WO 95/06128	03-02-1995	Dekalb Genetics		
	CT	EP 0293358	11-30-1988	Monsanto Co		
	CU	WO 92/000377	01-09-1992	Monsanto Co		
	CV	EP 0242236	10-21-1987	Plant Genetics Systems		
	CW	EP 0369367	05-23-1990	Lincoln Electric		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.¹ Applicant's unique citation designation number (optional).² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	4	of	15
-------	---	----	----

Complete if Known

Application Number	10/088,830
Filing Date	August 26, 2002
First Named Inventor	Crisanto Gutierrez-Armenta
Art Unit	1638
Examiner Name	Cynthia Collins
Attorney Docket Number	141183US01 (BTG0004-100)

[illegible]

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date/Filing Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
	CX	WO 03/104273	12-18-2003	ISIS Innovation		
	CY	WO 02/083722	10-24-2002	Koning		
	CZ	WO 03/066079	08-14-2003	Koning		
	DA	WO 03/096984	11-27-2003	Hausch		
	DB	WO 98/23960	06-04-1998	ISIS Innovation		
	DC	WO 92/20809	11-26-1992	Agracetus		
	DD	WO 99/20775	04-29-1999	Rhone-Poulenc		
	DE	EP 0693119	01-29-1997	Oxford Biosciences		

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 5 of 15

Complete if Known

Application Number	10/088,830
Filing Date	August 26, 2002
First Named Inventor	Crisanto Gutierrez-Armenta
Group Art Unit	1638
Examiner Name	Cynthia Collins
Attorney Docket Number	141183US1 (BTG0004-100)

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	DF	Ach, et al., "RRB1 and RRB2 encode maize retinoblastoma-related proteins that interact with a plant D-type cyclin and geminivirus replication protein," Mol. Cell Biol. (1997) 17:5077-5086.	
	DG	Albani, et al., "DcE2F, a functional plant E2F-like transcriptional activator from Daucus carota," J. Biol. Chem. (2000) 275:19258-19267	
	DH	Altschul "A protein alignment scoring system sensitive at all evolutionary distances," J Mol Evol (1993) 36(3):290-300.	
	DI	Altschul et al., "Basic local alignment search tool," J Mol Biol (1990) 215(3):403-410.	
	DJ	Anderson "Identification of the Immunodominant T-Cell Epitope in Agliadin Recognized by Coeliac Disease (CD) Patients in Vivo," (1999) A165.	
	DK	Anderson et al., "The a-gliadin gene family. II. DNA and protein sequence variation, subfamily structure, and origins of pseudogenes," Theor Appl Genet (1997) 95:59-65.	
	DL	Anderson, Robert et al.; in vivo antigen challenge in celiac disease identifies a single transglutaminase-modified peptide as the dominant a-gliadin T-cell epitope; Nature Medicine Vol. 6, No. 3, March 2000; 337-342.	
	DM	Arentz-Hansen et al., "Celiac lesion T cells recognize epitopes that cluster in regions of gliadins rich in proline residues," Gastroenterology (2002) 123(3):803-809.	
	DN	ARENZ-HANSEN, Helene; The Intestinal T Cell Response to α -Gliadin in Adult Celiac Disease is Focused on a Single Deamidated Glutamine targeted by Tissue Transglutaminase; J. Exp. Med. Volume 191, No. 4, 2-200- 603-612.	
	DO	Bandara, et al., "Functional synergy between DP-1 and E2F-1 in the cell cycle-regulating transcription factor DRTF1/E2F," EMBO J. (1993) 12:4317-4324.	
	DP	Bogre, et al., "Wounding induces the rapid and transient activation of a specific MAP kinase activity," Plant Cell (1997) 9:75-83.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

6

of

15

Complete if Known

Application Number	10/088,830
Filing Date	August 26, 2002
First Named Inventor	Crisanto Gutierrez-Armenta
Group Art Unit	1638
Examiner Name	Cynthia Collins
Attorney Docket Number	141183US1 (BTG0004-100)

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	DQ	Breeden and Nasmyth, "Regulation of the yeast HO gene," Cold Spring Harbor Symp. Quant. Biol. (1985) 50:643-650.	
	DR	Breeden, "Start-specific transcription in yeast," Curr. Topics Microbiol. Immunol. (1996) 208:95-127.	
	DS	Bunce et al., "Phototyping: comprehensive DNA typing for HLA-A, B, C, DRB1, DRB3, DRB4, DRB5 & DQB1 by PCR with 144 primer mixes utilizing sequence-specific primers (PCR-SSP)," <i>Tissue Antigens</i> (1995) 46(5):355-367.	
	DT	Dalta et al., "Plant promoters for transgene expression," <i>Biotechnology Ann Rev</i> (1997) 3:269-296.	
	DU	Database SwissProt Online! ID: GDA4-Wheat ACC:P04724, 13 August 1987 (Abstract)	
	DV	de Jager, et al., "Retinoblastoma proteins implants," <i>Plant Mol. Biol.</i> (1999) 41:295-299.	
	DW	de la Luna, et al., "Nuclear accumulation of the E2F heterodimer regulated by subunit composition and alternative splicing of a nuclear localization signal," <i>J. Cell Sci.</i> (1996) 109:2443-2452.	
	DX	Denecke, et al., "Plant and mammalian sorting signals for protein retention in the endoplasmic reticulum contain a conserved epitope," <i>EMBO J.</i> (1992) 11:2345-2355	
	DY	Devereux et al., "A comprehensive set of sequence analysis programs for the VAX," <i>Nucleic Acids Research</i> (1984) 12(1 Pt 1):387-395.	
	DZ	Dieterich et al., "Identification of tissue transglutaminase as the autoantigen of celiac disease," <i>Nature Medicine</i> (1997) 3(7):797-801.	
	EA	Doonan and Folbert, "Conserved and novel regulators of the plant cell cycle," <i>Curr. Opin. Cell Biol.</i> (1997) 9:824-830.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 7 of 15

Complete if Known

Application Number	10/088,830
Filing Date	August 26, 2002
First Named Inventor	Crisanto Gutierrez-Armenta
Group Art Unit	1638
Examiner Name	Cynthia Collins
Attorney Docket Number	141183US1 (BTG0004-100)

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	EB	Dyson, "The regulation of E2F by pRB-family proteins," Genes Dev. (1998) 12:2245-2262.	
	EC	Fields and Song, "A novel genetic system to detect protein-protein interactions," Nature (1989) 340:245-246.	
	ED	Fleckenstein "Gliadin T cell epitope selection by tissue transglutaminase in celiac disease. Role of enzyme specificity and pH influence on the transamidation versus deamidation process," J Biol Chem (2002) 277(37):34109-34116.	
	EE	Fountain, et al., "Isolation and characterization of a plant retinoblastoma-related gene from photoautotrophic cell suspension culture of Chenopodium rubrum L.," Plant Physiol. (1999) 119:363.	
	EF	Fraser et al., "Coeliac disease: In vivo toxicity of the putative immunodominant epitope," Gut (2003) 52(12):1698-1702.	
	EG	Fuerst, et al., "Modulation of cyclin transcript levels in cultured cells of Arabidopsis thaliana," Plant Physiol. (1996) 112:1023-1033.	
	EH	Girling, et al., "A new component of transcription factor DRTF1/E2F," Nature (1993) 362:83-87.	
	EI	GODKIN, A.S. et al., Identification of Coeliac Disease-Specific T Cell Epitope from A-Gliadin; Gut; Vol. 44, Suppl. 1, page A72, April 1999.	
	EJ	Grafi, et al., "A maize cDNA encoding a member of the retinoblastoma protein family: involvement in endoreduplication," Proc. Natl. Acad. Sci. USA (1996) 93:8962-8967.	
	EK	Greenberg et al., "Transglutaminases: multifunctional cross-linking enzymes that stabilize tissues," FASEB (1991) 5(15):3071-3077.	
	EL	Gutgemann et al., "Induction of rapid T cell activation and tolerance by systemic presentation of an orally administered antigen," Immunity (1998) 8:667-673.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 8 of 15

Complete if Known

Application Number	10/088,830
Filing Date	August 26, 2002
First Named Inventor	Crisanto Gutierrez-Armenta
Group Art Unit	1638
Examiner Name	Cynthia Collins
Attorney Docket Number	141183US1 (BTG0004-100)

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	EM	Gutierrez, "DNA replication and cell cycle in plants: learning from geminiviruses," EMBO J. (2000) 19:792-799.	
	EN	Gutierrez, "The retinoblastoma pathway in plant cell cycle and development," Curr Opin Plant Biol (1998), 1:492-497.	
	EO	Helin, et al., "Heterodimerization of the transcription factors E2F-1 and DP-1 leads to cooperative trans-activation," Genes Dev. (1993) 7:1850-1861.	
	EP	Helin, et al., "Inhibition of E2F-1 trans-activation by direct binding of the retinoblastoma protein," Mol. Cell Biol. (1993) 13:6501-6508.	
	EQ	Helin, et al., A cDNA encoding a pRB-binding protein with properties of the transcription factor E2F," Cell (1992) 70:337-350.	
	ER	Henikoff "Amino acid substitution matrices from protein blocks," Proc. Natl. Acad Sci USA (1992) 89(22):10915-10919.	
	ES	Huntley and Murray, "The plant cell cycle," Curr. Opin. Plant Biol. (1999) 2:440-446.	
	ET	Huntley, et al., "The maize retinoblastoma protein homologue ZmRb1 is regulated during leaf development and display conserved interactions with G1/S regulators and plant cyclins (D-type) proteins," Plant Mol. Biol. (1998) 37:155-169.	
	EU	Jung et al., "From combinatorial libraries to MHC ligand motifs, T-cell superagonists and antagonists," Biologicals (2001) 29(3-4):179-181.	
	EV	Karlin et al., "Applications and statistics for multiple high-scoring segments in molecular sequences," Proc Natl Acad USA (1993) 90(12):5873-5887.	
	EW	Kohler et al., "Continuous cultures of fused cells secreting antibody of predefined specificity," Nature (1975) 256(5517):495-497.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 9 of 15

Complete if Known

Application Number	10/088,830
Filing Date	August 26, 2002
First Named Inventor	Crisanto Gutierrez-Armenta
Group Art Unit	1638
Examiner Name	Cynthia Collins
Attorney Docket Number	141183US1 (BTG0004-100)

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	EX	Kosugi and Obashi, "PCF1 and PCF2 specifically bind to cis elements in the rice proliferating cell nuclear antigen gene," Plant Cell (1997) 9:1607-1619.	
	EY	Kozak, "At least six nucleotides preceding the AUG initiator codon enhance translation in mammalian cell," J Mol Bio (1987) 196(4):947-950.	
	EZ	Krek, et al., "Binding to DNA and the retinoblastoma gene product promoted by complex formation of different E2F family members," Science (1993) 262:1557-1560	
	FA	Kricka "Prospects for chemiluminescent and bioluminescent immunoassay and nucleic acid assays in food testing and the pharmaceutical industry," J Biolumin Chemilumin (1998) 13(4):189-193.	
	FB	Kumar et al., "Human genome search in celiac disease: mutated gliadin T-cell-like epitope in two human proteins promotes T-cell activation," Journal of Molecular Biology (2002) 319(3):579-599.	
	FC	Lalvani et al., "Rapid effector function in CD8+ memory T cells," J Exp Med (1997) 186(6):859-865.	
	FD	Lipman, et al., "Rapid and sensitive protein similarity searches," Science (1985) 227:1435-1441	
	FE	Lowndes, et al., "Control of DNA synthesis genes in fission yeast by the cell cycle gene cdc10," Nature (1992) 355:449-453.	
	FF	Lui, et al., "The Aradiopsis Cdc2a-interacting protein ICK2 is structurally related to ICK1 and is a potent inhibitor of cyclin-dependent kinase activity in vitro," Plant J. (2000) 21:379-386.	
	FG	Lundin et al., "Oats induced villous atrophy in coeliac disease," Gut[Machado, Lisa] (2003) 52(11):1649-1652.	
	FH	Madsen et al., "A humanized model for multiple sclerosis using HLA-DR2 and a human T-cell receptor," Nature Genetics (1999) 23(3):343-347.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 10 of 15

Complete if Known

Application Number	10/088,830
Filing Date	August 26, 2002
First Named Inventor	Crisanto Gutierrez-Armenta
Group Art Unit	1638
Examiner Name	Cynthia Collins
Attorney Docket Number	141183US1 (BTG0004-100)

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	FI	Maiuri et al., "In vitro activities of A-gliadin-related synthetic peptides: damaging effect on the atrophic coeliac mucosa and activation of mucosal immune response in the treated coeliac mucosa," Scand J Gastroenterol. (1996) 31(3):247-253.	
	FJ	Mantzaris et al., "In vivo toxicity of a synthetic dodecapeptide from A gliadin in patients with coeliac disease," Gastroenterol. (1991) 26(4):392-398.	
	FK	Martinez-Balbos, et al., "Regulation of E2F1 activity by acetylation," EMBO J. (2000) 19:662-671.	
	FL	Marzio, et al., "E2F family members are differently regulated by reversible acetylation," J. Biol. Chem. (2000) 275:10887-10892.	
	FM	McAdam et al., "Gliadin Specific Response by Small Intestinal T Cells," Peptide Binding to HLA Molecules and T Cells, Eighth International Symposium on Coeliac Disease, p. 17, (1999).	
	FN	Mironov, et al., "Cyclin-dependent kinases and cell division in plants: the nexus," Plant Cell (1999) 11:509-521.	
	FO	Molberg et al., "Tissue transglutaminase selectively modifies gliadin peptides that are recognized by gut-derived T cells in celiac disease," Nature Med (1998) 4(6):713-717.	
	FP	Moustakas et al., "Structure of celiac disease-associated HLA-DQ8 and non-associated HLA-DQ9 alleles in complex with two disease-specific epitopes," International Immunology (2000) 12(8):1157-1166.	
	FQ	Mowat et al., "Coeliac disease--a future for peptide therapy?," Lancet (2000) 356(9226):270-271.	
	FR	Mullighan et al., "High-resolution HLA-DQB1 typing using the polymerase chain reaction and sequence-specific primers," Tissue Antigens (1997) 50(6):688-692.	
	FS	Nakagami, et al., "Tobacco retinoblastoma-related protein phosphorylated by a distinct cyclin-dependent kinase complex with Cdc2/cyclin D in vitro," Plant J. (1999) 18:243-252.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 11 of 15

Complete if Known

Application Number	10/088,830
Filing Date	August 26, 2002
First Named Inventor	Crisanto Gutierrez-Armenta
Group Art Unit	1638
Examiner Name	Cynthia Collins
Attorney Docket Number	141183US1 (BTG0004-100)

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	FT	Nevins, "E2F: A link between the Rb tumor suppression protein and viral oncoproteins," Science (1992) 258:424-429.	
	FU	O'KEEFFE, J. et al. T cell proliferation, MGC class II restriction and cytokine products of gliadin-stimulated peripheral blood mononuclear cells (PBMC); Clin. Exp. Immunol.; 1999; 117:269-276.	
	FV	OKITA, T. et al., Evolution and Heterogeneity of the α -1 β -type and Y-type Gliadin DNA Sequences; The Journal of Biological Chemistry; Vol. 260, No. 13, July 5, 1985; pp. 8203-8213.	
	FW	Olerup et al., "HLA-DQB1 and -DQA1 typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours," Tissue Antigens (1993) 41(3):119-137.	
	FX	Ormonroyd, et al., "A new member of the DP family, DP-3, with distinct protein products suggests regulatory role for alternative splicing in the cell cycle transcription factor DRTF1/E2F," Oncogene (1995) 11:1437-1446.	
	FY	Ota et al., "T-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis," Nature (1990) 346(6280):183-187.	
	FZ	Ohtani and Nevins, "Functional properties of a Drosophila homolog of the E2F-1 gene," Mol. Cell Biol. (1994) 14:1603-1612	
	GA	Ouellette, et al., "Complexes containing the retinoblastoma gene product recognize different DNA motifs related to the E2F binding site," Oncogene (1992) 7:1075-1081	
	GB	Piper et al., "High Selectivity of Human Tissue Transglutaminase for Immunoactive Gliadin Peptides: Implications for Celiac Sprue," Biochemistry (2002) 41(1):386-393.	
	GC	Plebanski et al., "Protection from Plasmodium berghei infection by priming and boosting T cells to a single class I-restricted epitope with recombinant carriers suitable for human use," Eur J Immunol (1998) 28(12):4345-4355.	
	GD	Quarsten et al., "HLA binding and T cell recognition of a tissue transglutaminase-modified gliadin epitope," Eur J Immunol (1999) 29(8):2506-2514.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 12 of 15

Complete if Known

Application Number	10/088,830
Filing Date	August 26, 2002
First Named Inventor	Crisanto Gutierrez-Armenta
Group Art Unit	1638
Examiner Name	Cynthia Collins
Attorney Docket Number	141183US1 (BTG0004-100)

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	GE	Ramirez-Parra, et al., "Characterization of wheat DP, a heterodimerization partner of the palnt E2F transcription factor which stimulates E2F-DNA binding," FEBS Lett. (2000) 486:73-78.	
	GF	Ramirez-Parra, et al., "The cloning of plant E2F, a retinoblastoma-binding protein, reveals unique and conserved features with animal G1/S regulators," Nucl. Acids, Res. (1999) 27:3527-3533.	
	GG	Riou-Kamlichi, et al., "Cytokinin activation of Aradiopsis cell division through a D-type cyclin," Science (1999) 283:1541-1544.	
	GH	Sambrook, et al., "Molecular Cloning: A Laboratory Manual," Cold Spring Harbor Laboratory Press, 1989, Cold Spring Harbor, NY	
	GI	Sanford, et al., "Optimizing the biolistic process for diffesent biological applications," Methods Enzymol. (1993) 217:483-509.	
	GJ	Sardet, et al., "E2F-4 and E2F-5, to members of the E2F family, are expressed in the early phases of the cell cycle," Proc. Natl. Acad. Sci. USA (1995) 92:2403-2407.	
	GK	Scott, et al., "Model system for plant cell biology: GFP imaging in living onion epidermal cells," Biotechniques (1999) 26:1125-1132	
	GL	Sekine, et al., "Isolation and characterization of the E2F-like gene in plants," FEBS Lett. (1999) 460:117-122.	
	GM	Shoemaker, et al., EMBL Acc. No. AI939068, August 3, 1999	
	GN	Sjostrom et al., "Identification of a gliadin T-cell epitope in coeliac disease: general importance of gliadin deamidation for intestinal T-cell recognition," Scand J Immunol (1998) 48(2):111-115.	
	GO	Slansky and Farnum, "Introduction to the E2F family: protein structure and gene reguation," Curr. Topics Microbiol. Immunol. (1996) 208:1-30.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

13

of

15

Complete if Known

Application Number	10/088,830
Filing Date	August 26, 2002
First Named Inventor	Crisanto Gutierrez-Armenta
Group Art Unit	1638
Examiner Name	Cynthia Collins
Attorney Docket Number	141183US1 (BTG0004-100)

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	GP	Smith and Waterman, "Comparison of biosequences", Adv. Mathematics (1981) 2:482-489.	
	GQ	Suarez-Lopez and Gutierrez, "DNA replication of wheat dwarfgemini virus vectors: effects of origin structure and size," Virology (1997) 227:389-399.	
	GR	Tao, et al., "Subunit composition determines E2F DNA-binding site specificity," Mol. Cell Biol. (1997) 17:6994-7007	
	GS	Thureau et al., "Oral tolerance in a murine model of relapsing experimental autoimmune uveoretinitis (EAU): induction of protective tolerance in primed animals," Clin Exp Immunol (1997) 109(2):370-376.	
	GT	Tian et al., "Antigen-based immunotherapy for autoimmune disease: from animal models to humans?" Immunology Today (1999) 20(4):190-195.	
	GU	TRONCONE, R. et al., Cytokines produced by Gliadin-Specific T Cell Clines from the Coeliac Mucosa; Gastroenterology, Vol. 110, No. 4, p. A103, April 1996.	
	GV	Uhlig, H. et al., Role of Tissue Transglutaminase in Gliadin Binding to Reticular Extracellular Matrix and Relation to Coeliac Disease Autoantibodies; Autoimmunity, Vol. 28, pp. 185-195.	
	GW	Umeda, et al., "A distinct cyclin-dependent kinase-activating kinase of Arabidopsis thaliana," Proc. Natl. Acad. Sci. USA (1998) 95:5021-5026.	
	GX	Vader et al., "Specificity of Tissue Transglutaminase Explains Cereal Toxicity in Celiac Disease," Journal of Experimental Medicine (2002) 195(5):643-649.	
	GY	Vader et al., "The gluten response in children with celiac disease is directed toward multiple gliadin and glutenin peptides," Gastroenterology (2002) 122:1729-1737.	
	GZ	Vader et al., Proceedings 8th International Symposium Coeliac Disease.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 14 of 15

Complete if Known

Application Number	10/088,830
Filing Date	August 26, 2002
First Named Inventor	Crisanto Gutierrez-Armenta
Group Art Unit	1638
Examiner Name	Cynthia Collins
Attorney Docket Number	141183US1 (BTG0004-100)

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	HA	van de Wal "Glutenin is involved in the gluten-driven mucosal T cell response," Eur J Immunol (1999) 29(10):3133-3139.	
	HB	Van de Wal et al., "Coeliac disease: it takes three to tango!," Gut (2000) 46(5):734-737.	
	HC	Van de Wal et al., "Selective deamidation by tissue transglutaminase strongly enhances gliadin-specific T cell reactivity," The Journal of Immunology (1998) 161(4):1585-1588.	
	HD	VAN DE WAL, Y et al., Small intestinal T cells of celiac disease patients recognize a natural pepsin fragment of gliadin; Proc. Natl. Acad. Sci. Vol. 95, pp. 10050-10054, August 1998; Immunology.	
	HE	Varagona, et al., "Nuclear localization signal(s)-required for nuclear targeting of the maize regulatory protein Opaque-2," Plant Cell (1992) 4:1213-1227	
	HF	Vasil et al., "Herbicide Resistant Fertile Transgenic Wheat Plants Obtained by Microprojectile Bombardment of Regenerable Embryogenic Callus," Biotechnology (1992) 10:667-674.	
	HG	von Arnim et al., "Cloning vectors for expression of green fluorescent protein fusion proteins in transgenic plants," Gene (1998) 221:35-43.	
	HH	von Arnim, et al., "Light inactivation of Arabidopsis photomorphogenic repressor COP1 involves a cell-specific regulation of its nucleocytoplasmic partitioning," Cell (1994) 79:1035-1045	
	HI	Wang, et al., "ICK1, a cyclin-dependent protein kinase inhibitor from Arabidopsis thaliana interacts with both cdc2a and CycD3, and its expression is induced by abscisic acid," Plant J. (1998) 15:501-510.	
	HJ	Weiner et al., "Oral tolerance: cytokine milieu in the gut and modulation of tolerance by cytokines," Res Immunol (1997) 148(8-9):528-533.	
	HK	Wieser et al., "Coeliac active peptides from gliadin: large-scale preparation and characterization," Z Lebensm Unters Forsch (1992) 194(3):229-234.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 15 of 15

Complete if Known

Application Number	10/088,830
Filing Date	August 26, 2002
First Named Inventor	Crisanto Gutierrez-Armenta
Group Art Unit	1638
Examiner Name	Cynthia Collins
Attorney Docket Number	141183US1 (BTG0004-100)

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	HM	Xie, et al., "GRAB proteins, novel members of the NAC domain family, isolated by their interaction with a geminivirus protein," Plant Mol. Biol. (1999) 39:647-656.	
	HN	Xie, et al., "Identification and analysis of a retinoblastoma binding motif in the replication protein of a plant DNA virus: requirement for efficient viral DNA replication," EMBO J. (1995) 14:4073-4082.	
	HO	Xie, et al., "Plant cells contain a novel member of the retinoblastoma family of growth regulatory proteins," EMBO J. (1996) 15:4900-4908.	
	HP	Yoshida et al., "The oral administration of low-dose antigen induces activation followed by tolerization, while high-dose antigen induces tolerance without activation," Clin Immunol Immunopathol (1997) 82:207-215.	
	HQ	Zheng, et al., "Structural basis of DNA recognition by the heterodimeric cell cycle transcription factor E2F-DP," Genes Dev. (1999) 13:666-674.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.